Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines

Arthritis Care and Research

Volumn 62, Issue 6, 2010, Pages 791-799

  Nestoriuc, Yvonne ^a,b   Orav, E John ^a   Liang, Matthew H ^a   Horne, Robert ^c   Barsky, Arthur J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BIOLOGICAL RESPONSE MODIFIER; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALICYLIC ACID DERIVATIVE; STEROID;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEALTH BELIEF; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; OUTPATIENT; PAIN; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN ALLERGY; STOMACH PAIN; ULCER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COGNITIVE THERAPY; COHORT STUDIES; CULTURE; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGISTRIES; YOUNG ADULT;

EID: 77953113763     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20160     Document Type: Article

References (45)

1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001;41:192-199
2. Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008;178:1563-1569
3. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-627 (Pubitemid 34252015)
4. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-1116 (Pubitemid 37430324)
5. Larsen EB, Gerlach J. Subjective experience of treatment, side effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996;93:381-388 (Pubitemid 26189163)
6. FitzGerald M, Chan CK, Boulet LP. Medication use, asthma control and oropharyngeal side effects in a population of Canadian asthma patients. Proceedings of the American Thoracic Society; 2006 May 19-24; San Diego, California. Proc Am Thorac Soc 2006;3:A593.
7. Mohr D, Likosky W, Boudewyn A, Marietta P, Dwyer P, Van der Wende J, et al. Side effects profile and adherence in the treatment of multiple sclerosis with interferon β-1a. Mult Scler 1998;4:487-489 (Pubitemid 29042155)
8. Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups. Arch Intern Med 2006;166:155-160
9. Rief W, Nestoriuc Y, von Lilienfeld-Toal A, Dogan I, Schreiber F, Hofmann SG, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 2009;32: 1041-1056
10. Donnelly P, Lloyd K, Campbell H. Indomethacin in rheumatoid arthritis: an evaluation of its anti-inflammatory and side effects. Br Med J 1967;1:69-75.
11. Van Enverdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med 2002; 136:1-12.
12. Barsky AJ, Orav JE, Ahern DK, Rogers MP, Gruen SD, Liang MH. Somatic style and symptom reporting in rheumatoid arthritis. Psychosomatics 1999;40:396-403.
13. Rief W, Nestoriuc Y, Hofmann SG. The power of expectation: understanding the placebo and nocebo phenomenon. Soc Personal Psychol Compass 2008;2:1624-1637
14. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
15. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555-567 (Pubitemid 30029305)
16. Aikens JE, Neas DE, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med 2005;3:23-30.
17. Hunot V, Horne R, Leese MN, Churchill RC. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry 2007;9:91-99 (Pubitemid 46607462)
18. Gonzalez JS, Penedo FJ, Llabre MM, Duran RE, Antoni MH, Schneiderman N, et al. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med 2007;34:46-55. (Pubitemid 47481224)
19. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007; 45:334-341 (Pubitemid 47012382)
20. Treharne GJ, Lyons AC, Kitas GD. Medication adherence in rheumatoid arthritis: effects of psychosocial factors. Psychol Health Med 2004;9:337-349
21. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford) 2005;44:762-767 (Pubitemid 41487205)
22. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers and intentional nonadherers: application of the necessity-concerns framework. J Psychosom Res 2008;64:41-46 (Pubitemid 350297299)
23. Horne R. Patients' beliefs about treatment: the hidden determinant of treatment outcome? J Psychosom Res 1999;47: 491-495
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
25. Sox HC, Liang MH. The erythrocyte sedimentation rate: guidelines for rational use. Ann Intern Med 1986;104:515-523 (Pubitemid 16137814)
26. Ward M. Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. J Rheumatol 2003;31:884-895
27. Smolen JS, Eberl G, Breedveld FC, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
28. American Rheumatism Association Glossary Committee. New York NCAIL, 1982. Dictionary of the rheumatic diseases. I. Signs and symptoms. New York: Contact Associates International Ltd.; 1982.
29. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
30. Van der Heijde DM, van 't Hof MA, van Riel PL. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-181
31. Hays RD, Stewart AL. The structure of self-reported health in chronic disease patients. J Consult Clin Psychol 1990;2:22-30.
32. Kenny DA. Cross-lagged panel correlation: a test for spuriousness. Psychol Bull 1975;82:887-903.
33. Kenny DA, Harackiewick JM. Cross-lagged panel correlation: practice and promise. J Appl Psychol 1979;64:372-379
34. Little RJ. A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc 1988;83: 1198-1202
35. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods 2002;7:147-177
36. Erdfelder E, Faul F, Buchner A. GPOWER: a general power analysis program. Behav Res Methods Instrum Comput 1996; 28:1-11. (Pubitemid 126416697)
37. Muthen LK, Muthen BO. Mplus user's guide. Los Angeles (CA): Muthen & Muthen; 1998.
38. Berry D, Bradlow A, Bersellini E. Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditions. Rheumatology (Oxford) 2004;43:901-905 (Pubitemid 38996966)
39. De Klerk E, van der Heijde DM, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54. (Pubitemid 36077771)
40. Brus H, van de Laar M, Taal E, Rasker J, Wiegman O. Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. Patient Educ Couns 1999;36:57-64. (Pubitemid 28535156)
41. Park DC, Hertzog C, Leventhal H, Morrell RW, Leventhal E, Birchmore D, et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc 1999;47:172-183 (Pubitemid 29082717)
42. Kumar K, Gordon C, Toescu V, Buckley CD, Horne R, Nightingale PG, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and white British origin. Rheumatology (Oxford) 2008;47:690-697 (Pubitemid 351619214)
43. Goodacre LJ, Goodacre JA. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease modifying medication. Rheumatology (Oxford) 2004;43:583-586
44. Foster JM, van der Molen T, Caeser M, Hannaford P. The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiol Drug Saf 2008;17:278-296 (Pubitemid 351404039)
45. Rief W, Glombiewski JA, Barsky AJ. GASE: Generic Assessment of Side Effects in Clinical Trials. 2009. URL: www.gasescale.com.